

## Supplementary material

### Genetic landscape of idiopathic pulmonary fibrosis: A systematic review, meta-analysis and epidemiological evidence of case-control studies

Pooja Singh<sup>1,5</sup>, Debleena Guin<sup>3,5</sup>, Bijay Pattnaik<sup>2,4</sup>, Ritushree Kukreti<sup>1,5\*</sup>

1. Academy of Scientific and Innovative Research (AcSIR), CSIR- Institute of Genomics and Integrative Biology (CSIR-IGIB) Campus, New Delhi, India
2. Centre of Excellence for Translational Research in Asthma and Lung Diseases, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
3. Department of Bioinformatics, Delhi Technological University, Shahbad Daulatpur, Main Bawana Road, New Delhi, India
4. Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India
5. Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), New Delhi, India

#### Correspondence

Ritushree Kukreti,

Genomics and Molecular Medicine Unit,

CSIR- Institute of Genomics and Integrative Biology,

Mall Road, Delhi 110 007, India.

Phone: 91-11-27662202; Fax: 91-11-27667471;

Email: [ritus@igib.res.in](mailto:ritus@igib.res.in), [ritushreekukreti@gmail.com](mailto:ritushreekukreti@gmail.com)

## **Supplementary files:**

1. **Supplementary Table 1:** PRISMA checklist
2. **Supplementary Fig. 1:** Two-stage search strategy to identify and select IPF gene association studies.
3. **Supplementary Table 2:** Literature search: MeSH terms used, individually and in combination, with AND/OR Boolean operators in I<sup>st</sup> and II<sup>nd</sup> literature search strategy.
4. **Supplementary file 1:** Inclusion and exclusion criteria.
5. **Supplementary file 2:** Data extraction.
6. **Supplementary file 3:** Literature search and study selection.
7. **Supplementary Table 3:** Criteria for evaluation of epidemiological credibility.
8. **Supplementary Fig. 2:** PRISMA flow diagram for the inclusion and exclusion of studies exploring the role of genetic variants in IPF risk. The number of studies excluded on each step is represented as N.
9. **Supplementary Table 4:** Characteristics of included studies for assessment of the association between genetic variants and IPF susceptibility.
10. **Supplementary Table 5:** Details of quality assessment scoring for studies included in the meta-analysis based on modified Newcastle Ottawa Scale (NOS).
11. **Supplementary Table 6:** Summary of subgroup analysis findings based on ethnicity between IPF patients and healthy controls for genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), d) rs1800470 (*TGF-β1*).
12. **Supplementary Table 7:** Sensitivity analysis with pooled odds ratios (OR) for studies exploring the association of genetic variants with IPF susceptibility by removing one study each time.
13. **Supplementary Fig. 3:** Funnel plots showing publication bias among studies exploring IPF risk associated with genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), d) rs2076295 (*DSP*), e) rs12610495 (*DPP9*), f) rs1800470 (*TGF-β1*). Each point – represents a separate study for the indicated association or natural logarithm (log) of OR. A horizontal line means effect size.

**Supplementary Table 1: PRISMA checklist**


Section and Topic	Item #	Checklist item	Page No.
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	1
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	3
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	9(Supplementary file 1 of Supporting Information)
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	4, 7-8 (Table 2 of Supporting Information)
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	5, 9 (Supplementary file 2 of Supporting Information)
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were	9

Section and Topic	Item #	Checklist item	Page No.
		compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	(Supplementary file 2 of Supporting Information)
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	5
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	4,5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	6
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	5
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	6-7, Fig. 1, 9 (Supplementary file 3 of Supporting

Section and Topic	Item #	Checklist item	Page No.
			Information), 11 (Fig. 2 of Supporting Information)
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	8
Study characteristics	17	Cite each included study and present its characteristics.	7, 12-36 (Table 4 of Supporting Information), 24-35 (Table 1)
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	10, 42-43 (Fig. S2), 10, 40-41 (Table 7 of supporting information)
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	12-36 (Table 4 of Supporting Information)
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	23-34 (Table 1)
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	8-10, 35 (Table 2), 39 (Table 6 of Supporting Information)
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	8-10, 35 (Table 2)
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	10, 39-41 (Table 7 of Supporting Information)
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	10, 42-43 (Fig. 2)
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	10, 40-41 (Table 7 of supporting

Section and Topic	Item #	Checklist item	Page No.
			information)
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	11-13
	23b	Discuss any limitations of the evidence included in the review.	13-14
	23c	Discuss any limitations of the review processes used.	13-14
	23d	Discuss implications of the results for practice, policy, and future research.	14
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	4
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	14
Competing interests	26	Declare any competing interests of review authors.	14
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	15

**Supplementary Fig. 1:** Two-stage search strategy to identify and select IPF gene association studies.



**Supplementary Table 2:** Literature search: MeSH terms used, individually and in combination, with AND/OR Boolean operators in I<sup>st</sup> and II<sup>nd</sup> literature search strategy.

MeSH terms used for I <sup>st</sup> search strategy	
“idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”	
MeSH terms used for II <sup>nd</sup> search strategy	
rs35705950 (MUC5B)	“mucin5b”, “MUC5B”, “rs35705950”, “mucin”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”

rs2736100 ( <i>TERT</i> )	“telomerase reverse transcriptase”, “TERT”, “rs2736100”, “telomerase related gene”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs2609255 ( <i>FAM13A</i> )	“family with sequence similarity 13 member A”, “family with Sequence Similarity 13, Member A”, “FAM13A”, “rs2609255”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs2076295 ( <i>DSP</i> )	“desmoplakin”, “desmoplakins”, “DSP”, “rs2076295”, “cell-cell adhesion”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs12610495 ( <i>DPP9</i> )	“Dipeptidyl Peptidase 9”, “DPP9”, “rs12610495”, “DP9”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs1800470 ( <i>TGF-β1</i> )	“TGF-beta1”, “TGF-beta-1”, “TGFbeta”, “transforming growth factor beta1”, “TGFB1”, “rs1800470”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs7934606 ( <i>MUC2</i> )	“MUC2”, “mucin2”, “mucin-2”, “rs7934606”, “mucin”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs1278769 ( <i>ATP11A</i> )	“ATP11A”, “ATPase Phospholipid Transporting 11A”, “rs1278769”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs5793295 ( <i>LRRC34</i> )	“Leucine Rich Repeat Containing 34”, “Leucine-Rich Repeat-Containing 34”, “LRRC34”, “rs5793295”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs111521887 ( <i>TOLLIP</i> )	“TOLLIP”, “Toll Interacting Protein”, “rs111521887”, “Toll-Interacting Protein”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”



### **Supplementary file 1: Inclusion and exclusion criteria**

Articles meeting the following criteria were eligible to be included in the study: (i) studies evaluating the association of genetic variants in IPF susceptibility, (ii) the study design must be a case-control design based on unrelated individuals, (iii) IPF patients must have been diagnosed by radiological, histopathological examination or based on American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/ Latin-American Thoracic Association (ALAT) diagnostic criteria. Articles were excluded based on the following criteria (i) review articles, meta-analysis, editorials, commentary, errata, and news articles, (ii) study design based on family or sibling pairs, (iii) non-human studies, (iv) non-English articles, (v) recruited IPF patients with comorbid conditions. Additionally, for meta-analyses, articles were excluded if (vi) insufficient data was provided for estimating odds ratios (OR) with 95% confidence interval (CI), (vii) the genotype distribution in controls was inconsistent with Hardy-Weinberg equilibrium (HWE).

### **Supplementary file 2: Data extraction**

The following data were extracted: first author, year of publication, ethnicity of the studied population (where not conveyed, the country in which the study was carried out was considered), diagnostic criteria for IPF patients, number of participants (total and male/female), the mean age of cases and controls, genes, genetic variants, risk allele or genotype, statistical parameters [p-value, OR and 95% CI] of allelic model (for insufficient data for calculation, genotypic data is represented), genotyping methods used. Global allele frequency of risk allele was determined according to the dbSNP database (54). Authors were contacted where data required for conducting meta-analysis was not provided. Publications were excluded if responses were not received after two weeks. In the case of repeated or overlapping studies, the one with the most subjects and sufficient data was included.

### **Supplementary file 3: Literature search and study selection**


Out of 4032 excluded studies, 908 studies were grey literature (Review, systematic review and meta-analysis), one study is in a language other than English, twenty-nine studies discussed IPF with comorbid condition, thirty studies were on familial IPF/pulmonary fibrosis (PF)/ idiopathic interstitial pneumonias (IIP) (as the current study focuses on sporadic IPF), 109 studies were conducted on animal or *in vitro* models for IPF, 1637 studies were not related to IPF, 1112 studies were related to IPF but do not talk about genetics, 104 non-genetic studies, nine studies talked about the genetics of IPF progression and survival, seventy-eight studies were related to therapeutics and drugs used in IPF, in twelve studies abstract was not found and three studies had non-significant results for the association of genetic variants and IPF susceptibility.

**Supplementary Table 3:** Criteria for evaluation of epidemiological credibility.

<b>Criteria</b>	<b>Categories</b>
Amount of evidence	A: Sample size* for the rarer allele in the meta-analysis is greater than 1000.
	B: Sample size* for the rarer allele in the meta-analysis is between 100-1000.
	C: Sample size* for the rarer allele in the meta-analysis is less than 100.
Replication	A: Extensive replication including at least one well-conducted meta-analysis, and similarity of phenotyping, genotyping and analytical models across studies.
	B: Well replicated without any conducted meta-analysis, and similarity of phenotyping, genotyping and analytical models across studies.
	C: No association, failed replication, and no independent replication.
Protection from bias	A: The summary effect size is greater than 1.15 or less than 0.87, and the following four situations do not occur: 1) nominal statistical significance is lost with the exclusion of the first published study; 2) nominal statistical significance is lost with the exclusion of studies where HWE is violated; 3) small study effects.
	B: There is no evidence of bias that would invalidate an association, but important information is missing
	C: The summary effect size is 0.87–1.15, or at least one of the following four situations occurs: 1) nominal statistical significance is lost with the exclusion of the first published study; 2) nominal statistical significance is lost with the exclusion of studies where HWE is violated; 3) small study effects.

\*calculated by multiplying population specific minor allele frequency with total number of cases and controls included in meta-analysis. HWE, Hardy Weinberg equilibrium.

**Supplementary Fig. 2:** PRISMA flow diagram for the inclusion and exclusion of studies exploring the role of genetic variants in IPF risk. The number of studies excluded on each step is represented as N.



**Supplementary Table 4:** Characteristics of included studies for assessment of the association between genetic variants and IPF susceptibility.

Sl. No	Study Name (year)	Population/Ethnicity	Diagnostic criteria	Sample characteristics						Gene	SNP	Risk allele/genotype	OR (95% CI)	p-value	Method	Global allele frequency (risk allele)	
				Total (N)	Case			Control									
					N	M/F	Age in years [mean±SD/mean (range)]	N	M/F								Age in years [mean±SD/mean (range)]
1	Dhindsa et al. (2021) <sup>1</sup>	European	ATS/ERS guidelines 2013	119,807	752	-	71.0	119,055	-	-	<i>MUC2</i>	rs7944723	C	1.86 (1.66-2.07)	$1.71 \times 10^{-26}$	Whole exome sequencing	0.122 “
											<i>MUC5AC</i>	rs28403537	T	2.78 (2.35-3.29)	$6.96 \times 10^{-26}$		0.046 “
											<i>MUC2</i>	rs6421972	T	1.41 (1.27-1.55)	$4.30 \times 10^{-11}$		0.390 “
											<i>TOLLIP</i>	rs3750920	T	1.37 (1.24-1.51)	$9.63 \times 10^{-10}$		0.424 “
											<i>MUC5B</i>	rs908229	C	0.75 (0.67-0.82)	$1.90 \times 10^{-8}$		0.443 “
											<i>SPDL1</i>	rs116483731	A	2.87 (2.03-4.07)	$2.40 \times 10^{-7}$		0.006 “
				198,014	1028	-	-	196,986	-	-	<i>SPDL1</i>	rs116483731	A	3.13 (2.37-4.14)	$1.00 \times 10^{-15}$		0.006 “
2	Bonella et al. (2021) <sup>2</sup>	Caucasian	ATS/ERS/JRS/ALAT guidelines 2011 and ATS/ERS/JRS/ALAT guidelines 2018	112	62	43/8	63.5±11	50	37/13	42.0±2	<i>MUC5B</i>	rs35705950	T	5.36 (2.46-11.69)	<0.0001	RT-PCR using TaqMan	0.046
3	Allen et al. (2020) <sup>3</sup>	European	(ATS/ERS guidelines 2000 and ATS/ERS/JRS/ALAT	1125 <sup>9D</sup>	2668 [541 <sup>α</sup> , 1,515 <sup>β</sup> , 612 <sup>γ</sup> ]	1818/80 9[355/145] <sup>α</sup> , (1030/48	(68.0±3.0/ 63.0±7.5) <sup>α</sup> , 66.0±9.5 <sup>β</sup> , (70/65.0) <sup>γ</sup>	8591 [542 <sup>α</sup> , 4,683 <sup>β</sup> , 3,366 <sup>γ</sup> ]	4891 /3,668 [(240 /270) <sup>α</sup> , (229 5/23	-	<i>KIF15</i>	rs78238620	A	1.58 (1.37-1.83)	$5.12 \times 10^{-10}$	Affymetrix 6.0 SNP array <sup>α</sup> ; Illumina Human 660W Quad BeadChip <sup>β</sup> ; Affymetrix UK BiLEVE	0.054
											<i>MAD1L1</i>	rs12699415	A	1.28 (1.19-1.37)	$7.15 \times 10^{-13}$		0.409
											<i>DEPTOR</i>	rs28513081	G	0.82 (0.76-0.87)	$1.20 \times 10^{-9}$		0.454
											<i>RTEL1</i>	rs41308092	A	2.12 (1.67-2.69)	$7.65 \times 10^{-10}$		0.007



			(ATS/ERS guidelines 2000 and ATS/ERS/JRS/ALAT guidelines 2011) <sup>α</sup> ; ATS/ERS guidelines 2002 <sup>β</sup> ; (ATS/ERS guidelines 2002 and ATS/ERS/JRS/ALAT guidelines 2011) <sup>γ</sup> ; ATS/ERS/JRS/ALAT guidelines 2011 <sup>^</sup>	24589 <sup>M</sup>	4124 [541 <sup>α</sup> , 1,515 <sup>β</sup> , 612 <sup>γ</sup> , 792 <sup>@</sup> , 664 <sup>^</sup> ]	2888/1195 [(355) <sup>α</sup> , (1030) <sup>β</sup> , (433/179) <sup>γ</sup> , (582/210) <sup>@</sup> , (488/176) <sup>^</sup> ]	(68.0±3.0/63.0±7.5) <sup>α</sup> , 66.0±9.5 <sup>β</sup> , (70/65) <sup>γ</sup> , (69/58) <sup>@</sup> , 68 <sup>^</sup>	20465 [542 <sup>α</sup> , 4,683 <sup>β</sup> , 3,366 <sup>γ</sup> , 10,000 <sup>@</sup> , 1,874 <sup>^</sup> ]	12,609/7,824 [(240/270) <sup>α</sup> , (2295/2388) <sup>β</sup> , (2356/10) <sup>γ</sup> , (7210/2790) <sup>@</sup> , (508/1366) <sup>^</sup> ]	-	<i>KIF15</i>	rs78238620	A	1.54 (1.38-1.73)	4.05 × 10 <sup>-14</sup>	Affymetrix 6.0 SNP array <sup>α</sup> ; Illumina Human 660W Quad BeadChip <sup>β</sup> ; Affymetrix UK BiLEVE array(cases) <sup>###</sup> /Affymetrix UK BiLEVE and UK Biobank arrays (control) <sup>γ</sup> ; Affymetrix UK Biobank and Spain Biobank arrays (cases) <sup>@</sup> , Affymetrix UK BiLEVE and UK Biobank arrays (control) <sup>@</sup> ; HiSeq X Ten platform (Illumina) <sup>^</sup>	0.054	
												<i>MADILI</i>	rs12699415	A	1.28 (1.21-1.35)	9.38 × 10 <sup>-20</sup>		0.409
												<i>DEPTOR</i>	rs28513081	G	0.83 (0.79-0.88)	1.93 × 10 <sup>-11</sup>		0.454
												<i>RTELI</i>	rs41308092	A	1.82 (1.51-2.19)	2.24 × 10 <sup>-10</sup>		0.007
4	Arimura-Omori et al. (2020) <sup>4</sup>	Japanese	ATS/ERS/JRS/ALAT guidelines 2011	534	155 [include 7 families 1 IPF]	113/42	74.0 (69-78)	379	283/96	58 (48-65)	<i>TERT</i>	rs2736100	T	1.75 (1.31-2.33)~	0.0001~	RT-PCR using TaqMan fluorescent probes	0.515	
5	Moore et al. (2019) <sup>5</sup>	non-Hispanic whites	ATS/ERS/JRS/ALAT guidelines 2018	7588	3146	NA	NA	4442	-	-	<i>TERC</i>	rs2293607	CT vs TT; CC vs TT	1.27 (1.15-1.41); 1.82 (1.50-1.41)	-	Deep sequencing (HiSeq 4000 sequencer)	0.269	
											<i>FAM13A</i>	rs2609260	CT vs TT; CC vs TT	1.38 (1.25-1.54); 2.09 (1.65-2.64)	-		0.239	
											<i>TERT</i>	rs4449583	CT vs CC; TT vs CC	0.66 (0.59-0.73); 0.47 (0.39-0.56)	-		0.323	

											<i>DSP</i>	rs2076295	GT vs TT; GG vs TT	1.27 (1.13-1.43); 2.03 (1.78-2.33)	-		0.432
											<i>ZKSCAN1</i>	rs6963345	AG vs GG; AA vs GG	1.35 (1.21-1.50); 1.69 (1.47-1.96)	-		0.301
											<i>OBFC1/STNI</i>	rs2488000	T	0.70 (0.62-0.80)	-		0.108
											<i>MUC5B</i>	rs35705950	TG vs GG; TT vs GG	5.31 (4.76-5.92); 19.01 (13.49-26.78)	-		0.046
											<i>ATP11A</i>	rs1278769	AG vs GG; AA vs GG	0.79 (0.71-0.88); 0.65 (0.57-0.90)	-		0.233
											<i>IVD</i>	rs35700143	CT vs TT; CC vs TT	0.76 (0.68-0.85); 0.65 (0.56-0.74)	-		0.491
											<i>DPP9</i>	rs12610495	GA vs AA; GG vs AA	1.25 (1.13-1.38); 1.64 (1.39-1.93)	-		0.183
6	Liu et al. (2020) <sup>6</sup>	Chinese	ATS/ERS/JRS/ALAT guidelines 2011	378	253	169/84	65.4±11.1	125	84/41	65.3±10.8	<i>HYALI</i>	rs117179004	A	2.27 (1.27-4.07)	0.006	Ion Torrent platform (Thermo Fisher)	0.013
				387	162	99/63	64.2±10.9	225	109/73	60.9±10.5	<i>HYALI</i>	rs117179004	A	2.18 (1.32-3.61)	0.002	Big Dye v.1.1 terminator cycle sequencing kit and Applied Biosystems 3500xl capillary sequencer (Applied Biosystems)	0.013
7	Deng et al. (2019) <sup>7</sup>	Han Chinese	ATS/ERS/JRS/ALAT guidelines 2011	378	253	170/83	65.4±11.1 [age means onset age]	125	84/41	65.3±10.8	<i>CRI</i>	rs3737002	T	1.77 (1.28-2.45)	0.001	Ion Torrent Proton	0.248
											<i>CRI</i>	rs2296160	G	1.54 (1.13-2.09)	0.006		0.171
											<i>TGF-β1</i>	rs1800470	A	1.47 (1.08-2.00)	0.013		0.454
											<i>MUC5B</i>	rs35705950	T	4.84 (1.12-20.94)	0.018		0.046

8	Wang et al. (2019) <sup>8</sup>	Chinese	ATS/ERS/JRS/ALAT guidelines 2018	279	79	68/11	64.2±8.86	200	NA	NA	<i>MUC5B</i>	rs868903	C	1.46 (1.01-2.13)~	0.042	PCR	0.489
											<i>TERT</i>	rs2853676	A	0.57 (0.33-0.98)~	0.041		0.251
9	Lorenzo-Salazar et al. (2019) <sup>9</sup>	European-American	ATS/ERS/JRS/ALAT guidelines 2011	652 (60.8% samples were from Noth I. et al., 2013)	181	138/43	67.0	501	-	-	<i>MUC5AC</i>	rs371630624	C	1942(245.6-15360)	$7.18 \times 10^{-13}$	HiSeq 2500 (Illumina, Inc.)	0.000
											<i>MUC5AC</i>	rs34474233	A	4.08 (2.56-6.49)	$2.99 \times 10^{-9}$		0.022
											<i>MUC5AC</i>	rs34815853	A	4.01 (2.52-6.38)	$4.15 \times 10^{-9}$		0.021
											<i>MUC5B</i>	rs12802931	G	3.76 (2.73-5.16)	$3.72 \times 10^{-16}$		0.073
											<i>MUC5B</i>	rs35705950	T	6.18 (4.28-8.93)	$2.69 \times 10^{-22}$		0.046
											<i>MUC5B/RP11-532E4.2</i>	rs200243273	C	0.27 (0.17-0.43)	$3.55 \times 10^{-8}$		0.294
											<i>CTD-224506.1</i>	rs4963073	G	3.23 (2.12-4.921)	$4.91 \times 10^{-8}$		0.386
											<i>CTD-224506.2</i>	rs4963072	G	3.34 (2.19-5.11)	$2.63 \times 10^{-8}$		0.387
											-	rs71469892	G	0.22 (0.15-0.31)	$2.15 \times 10^{-16}$		0.232
											-	rs145898170	G	0.47 (0.36-0.62)	$4.71 \times 10^{-8}$		-
											-	rs199838022	C	0.45 (0.34-0.57)	$7.14 \times 10^{-9}$		-
											-	rs12586854	T	0.18 (0.12-0.26)	$6.81 \times 10^{-19}$		0.455
											-	rs11157543	C	0.13 (0.07-0.22)	$5.97 \times 10^{-14}$		0.344
											-	rs11157544	C	0.30 (0.21-0.41)	$1.37 \times 10^{-13}$		0.436
											-	rs12586856	G	0.18 (0.11-0.29)	$3.77 \times 10^{-13}$		0.417
											-	rs11157545	T	0.44 (0.34-0.59)	$7.81 \times 10^{-9}$		0.522
											-	rs183643415	A	0.04 (0.01-0.12)	$2.77 \times 10^{-8}$		0.108
											-	rs150322840	T	0.13 (0.07-0.24)	$3.90 \times 10^{-10}$	0.151	
											-	rs8005465	A	0.37 (0.27-0.51)	$4.41 \times 10^{-10}$	0.472	



											-	rs543453148	A	25.22 (8.29-76.73)	$1.30 \times 10^{-8}$		0.001
											-	rs12890180	G	0.39 (0.28-0.53)	$2.91 \times 10^{-9}$		0.456
											-	rs73251857	G	0.06 (0.02-0.14)	$9.59 \times 10^{-10}$		0.082
											-	rs7141653	C	0.25 (0.17-0.37)	$1.65 \times 10^{-11}$		0.317
											-	rs7145329	T	0.34 (0.24-0.49)	$2.59 \times 10^{-9}$		0.332
											-	rs4900770	A	0.38 (0.28-0.53)	$9.10 \times 10^{-9}$		0.452
											-	rs58731325	G	0.34 (0.25-0.47)	$7.35 \times 10^{-11}$		0.495
											<i>RP11-7023.1</i>	rs115811519	C	4.93 (2.83-8.58)	$1.68 \times 10^{-8}$		0.191
											<i>CTC-501010.1</i>	rs56383763	C	0.07 (0.03-0.16)	$1.75 \times 10^{-9}$		0.086
											<i>CRHRI</i>	rs373417	T	0.10 (0.05-0.20)	$1.24 \times 10^{-10}$		0.086
												rs7221124	A	0.04 (0.02-0.09)	$6.70 \times 10^{-14}$		0.359
												rs55938136	A	151.90 (62.14-371.50)	$3.37 \times 10^{-28}$		0.309
											<i>KANSLI</i>	rs11870844	A	3.98 (2.82-5.62)	$3.85 \times 10^{-15}$		0.333
												rs371996525	A	0.04 (0.02-0.11)	$2.17 \times 10^{-10}$		0.135
												rs142920272	C	0.10 (0.05-0.21)	$7.45 \times 10^{-11}$		0.185
											<i>KANSLI/LRRC37A</i>	rs2668637	G	5.32 (3.09-9.13)	$1.43 \times 10^{-9}$		0.037
												rs2696618	C	6.74 (4.02-11.31)	$5.09 \times 10^{-13}$		0.173
European	ATS/ERS criteria 2002 and ATS/ERS/JRS/ALAT guideline s 2011	3968 (samples from Allen et al., 2017)	602	426/176	70.0±8.4	3366	2356.0/1010.0	65±5.5			<i>MUC5AC</i>	rs34474233	A	3.15 (2.37-4.21)	$4.10 \times 10^{-14}$	Affymetrix Axiom UK BiLEVE array (Affymetrix) and Affymetrix Axiom UK Biobank array (Affymetrix)	0.022
												rs34815853	A	3.16 (2.37-4.20)	$4.13 \times 10^{-14}$		0.021
												rs12802931	G	2.42 (2.02-2.90)	$6.07 \times 10^{-22}$		0.073
												rs35705950	T	4.11 (3.31-5.11)	$1.86 \times 10^{-37}$		0.046
												<i>CTD-224506.1</i>	rs4963072	G	1.29 (1.08-1.54)		$5.30 \times 10^{-3}$

											<i>CTC-501010.1</i>	rs56383763	C	0.82 (0.68-0.98)	$2.42 \times 10^{-2}$		0.086
											<i>CRHR1</i>	rs373417	T	0.82 (0.69-0.98)	$2.72 \times 10^{-2}$		0.086
											<i>KANSL1</i>	rs371996525	A	0.80 (0.67-0.95)	$1.26 \times 10^{-2}$		0.135
												rs142920272	C	0.83 (0.69-0.98)	$3.07 \times 10^{-2}$		0.185
											<i>KANSL1/LRRC37A</i>	rs2696618	C	1.25 (1.05-1.49)	$1.05 \times 10^{-2}$		0.173
10	Dressen et al. (2018) <sup>10</sup>	Caucasian	ATS/ERS/JRS/ALAT guidelines 2011	3384	1510	1119/391	67.3±7.9	1874	507/1367	56.38±9.32	<i>MUC5B</i>	rs35705953	T	4.98 (4.40-5.65)	<0.0001	Illumina X10 sequence	0.046
											<i>TERT</i>	rs2736100	C	0.75 (0.68-0.83)	<0.0001		0.515
11	Daniil et al. (2018) <sup>11</sup>	European	ATS/ERS/JRS/ALAT guidelines 2018	244	40	34/6	68.8±8.3	204	-	-	<i>tRNA</i>	rs28358279*	C	18.96 (5.66-63.52)~	<0.001	PCR	0.102 “
												rs41456348*	C	14.51 (4.21-50.01)~	<0.001		0.022 “
												rs527236198*	A	106.96 (6.02-1898.22)~	<0.001		0.078 “
												rs1556423293*/A7472T	T	14.43 (2.69-77.31)~	0.002		-
											<i>ND3</i>	rs2853826*	G	3.20 (1.26-8.16)~	<0.001		0.169 “
												rs28358278*	T	50.75 (6.14-419.45)~	<0.001		0.028 “
											<i>16S rRNA</i>	C3157T	T	91.56 (5.10-1640.98)~	<0.001		-
											<i>ND2</i>	rs3020602*	C	63.36 (3.42-1171.32)~	<0.001		0.007 “
											<i>CYB</i>	G15884C	C	11.22 (1.98-63.55)~	0.007		-
											<i>COII</i>	G8251A	A	5.68 (1.56-20.66)~	0.012		-
											<i>16S rRNA</i>	A3136T	T	38.17 (1.93-754.28)~	0.004		-
											<i>CYB</i>	rs1603225535*	T	26.55 (1.25-564.09)~	0.026		0.0002 “
12	Allen et al. (2017) <sup>G12</sup>	European	ATS/ERS guidelines 2002 and ATS/ERS	3968 <sub>D</sub>	602	426/176	70.0±8.4	3,366	2356/1010	65.0±5.5	<i>CD1C</i>	rs147562345	T	4.45 (2.47-8.05)	$2.90 \times 10^{-6}$	Affymetrix Axiom UK	0.003
											<i>CFH</i>	rs560105094*/chr1:196625450	G	3.27 (2.12-5.04)	$5.09 \times 10^{-7}$	BiLEVE array (cases); Affymetrix	0.0005(gnomAD)

/JRS/AL  
AT  
guidelines 2011

<i>SRD5A2</i>	rs191031841	T	3.07 (2.21-4.27)	$1.80 \times 10^{-10}$	Axiom UK BiLEVE array and Affymetrix Axiom UK Biobank array (controls)	0.007
<i>TTC27</i>	rs6726541	G	3.78 (2.62-5.46)	$1.42 \times 10^{-12}$		0.389
-	rs74266324	A	0.45 (0.34-0.59)	$4.56 \times 10^{-9}$		0.284
-	rs33938858	C	0.20 (0.10-0.39)	$3.61 \times 10^{-9}$		0.326
-	rs555288190*/chr2:138817685	G	47.8 (6.90-332)	$1.65 \times 10^{-6}$		0.0005 (gnomAD)
<i>FAM47E</i>	rs34369701	A	0.29 (0.16-0.54)	$3.73 \times 10^{-6}$		0.199
-	rs28673968	C	0.47 (0.38-0.58)	$2.04 \times 10^{-12}$		0.472
-	rs112863361	A	0.022 (0.001-0.36)	$1.60 \times 10^{-9}$		0.031
<i>NDUFAF2</i>	rs140507420	G	2.98 (1.98-4.48)	$5.64 \times 10^{-7}$		0.007
-	rs150626307	A	154 (21.0-1136)	$2.81 \times 10^{-7}$		0.000
<i>DSP</i>	rs2076295	G	1.67 (1.44-1.92)	$4.14 \times 10^{-12}$		0.432
<i>C6orf10</i>	rs9268159	T	0.43 (0.32-0.58)	$2.19 \times 10^{-8}$		0.185
-	rs208501	T	1.83 (1.51-2.22)	$8.45 \times 10^{-10}$		0.183
<i>FYN</i>	rs1409839	C	0.53 (0.42-0.67)	$1.10 \times 10^{-7}$		0.365
<i>MRPL13</i>	rs562453723*/chr8:121446432	T	18.10 (6.07-53.9)	$6.69 \times 10^{-7}$		0.000
-	rs10117639	C	25.30 (6.47-98.8)	$4.01 \times 10^{-6}$		0.112
<i>MOB3B</i>	rs118048878	A	0.03 (0.002-0.45)	$1.50 \times 10^{-7}$		0.007
<i>MOB3B</i>	rs1975503	C	0.15 (0.05-0.44)	$1.27 \times 10^{-6}$		0.117
<i>REEP3</i>	chr10:65359362	T	36.40 (7.75-172)	$1.16 \times 10^{-6}$		-
-	rs776241108*/chr10:77228877	A	21.10 (6.25-70.9)	$7.53 \times 10^{-7}$		0.001 (gnomAD)



		Hispanic white <sup>β</sup>	ATS/ERS/JRS/AL AT guidelines 2011) <sup>α</sup> and ATS/ERS guidelines 2002 <sup>β</sup>		161 6 <sup>β</sup>	7) <sup>α</sup> , (109 0/52 6) <sup>β</sup>		468 3 <sup>β</sup>	<sup>α</sup> , (228 9/23 94) <sup>β</sup> ]		<i>MUC5B</i>	rs3570595 0	T	2.46 (2.13- 2.85)	3.13 × 10 <sup>-34</sup>	Illumina 660 Quad beadchip <sup>β</sup>	0.046
											<i>AKAP13/KLHL25</i>	rs6202527 0	A	1.22 (1.11- 1.33)	9.96 × 10 <sup>-6</sup>		0.113
		European , American - European <sup>α</sup> and non- Hispanic white <sup>β</sup>	ATS/ERS guideline s 2000, ATS/ERS guideline s 2002 and ATS/ERS /JRS/AL AT guideline s 2011	1132 1 <sup>M</sup>	276 0 [602 , 542 <sup>α</sup> , 161 6 <sup>β</sup> ]	1,90 1/85 9 [(42 6/17 6), (385 /157 ) <sup>α</sup> , (109 0/52 6) <sup>β</sup> ]	70.0±8.4, 68.0±3.0 <sup>α</sup> , 65.5±9.5 <sup>β</sup>	8,56 1 [33 66, 512 , 468 3 <sup>β</sup> ]	4,887 /367 4 [ (235 6/10 10), (242/ 270) <sup>α</sup> , (228 9/23 94) <sup>β</sup> ]	65.0±5 .5, 63.0±7 .5 <sup>α</sup>	<i>DSP</i>	rs2076295	G	1.44 (1.35- 1.54)	7.81 × 10 <sup>-28</sup>	Affymetrix Axiom UK BiLEVE array (discovery cases); Affymetrix Axiom UK BiLEVE array and Affymetrix Axiom UK Biobank array (discovery controls), Affymetrix Genome- Wide Human SNP 6.0 Array <sup>α</sup> ; Illumina 660 Quad beadchip <sup>β</sup>	0.432
											<i>MUC5B</i>	rs3570595 0	T	2.89 (2.56- 3.26)	1.12 × 10 <sup>-66</sup>		0.046
											<i>AKAP13/KLHL25</i>	rs6202527 0	A	1.27 (1.18- 1.37)	1.32 × 10 <sup>-9</sup>		0.113
13	Petrovski et al. (2017) <sup>13</sup>	European	ATS/ERS/JRS/AL AT guidelines 2011	525	183	-	-	342	-	-	<i>MUC5B</i>	rs3570595 0	T	4.0 (2.8–5.6)	3.1 × 10 <sup>-17</sup>	Illumina HiSeq 2000 or 2500 sequencer	0.046
14	Hirano et al. (2016) <sup>14</sup>	Japanese	ATS/ERS criteria 2002	375	65	55/1 0	65.8±9.9	310	255/ 55	50.6±7 .8	<i>FAM13A</i>	rs2609255	G	1.78 (1.29- 2.44)	<0.001	PCR	0.348
15	Yamaguchi et al. (2016) <sup>15</sup>	Japanese	ATS/ERS/JRS/AL AT guidelines 2011	390	87	76/1 1	67.5±9.9	303	248/ 55	50.5±7 .8	<i>AGER</i>	rs2070600	CT+TT vs CC	1.84 (1.08-3.1)	0.021	PCR	0.072

16	Kishore et al. (2016) <sup>16</sup>	European	ATS/ERS criteria 2000, ATS/ERS criteria 2001 and ATS/ERS/JRS/ALAT guidelines 2011	261	165	125/40	67.9±11.60	96	45/51	34.5±8.94	<i>MUC5B</i>	rs35705950	T	5.23 (3.06-8.94)	1.80 × 10 <sup>-11</sup>	Sequenom MassARRAY platform integrating iPLEX® SBE reaction and MassARRAY® technology (Agena Bioscience, San Diego, CA, USA) based MALDI-TOF MS assay	0.046
											<i>IL-1α</i>	rs1800587	T	0.68 (0.99-0.46)	4.94 × 10 <sup>-2</sup>		-
											<i>TF</i>	rs1799899	A	2.06 (1.12-3.78)	1.87 × 10 <sup>-2</sup>		-
											<i>MUC2</i>	rs7934606	A	2.18 (1.50-3.16)	3.73 × 10 <sup>-5</sup>		0.380 “
17	Van der Vis et al. (2015) <sup>17</sup>	Caucasian	ATS/ERS criteria 2002 and ATS/ERS criteria 2013 and ATS/ERS/JRS/ALAT guidelines 2011	364	115	97/18	63.5±11.0	249	-	-	<i>MUC5B</i>	rs35705950	T	3.60 (2.37-5.55)~	5.0 × 10 <sup>-10</sup>	TaqMan SNP genotyping assay (PCR)	0.046
18	Aquino-Gálvez et al. (2015) <sup>18</sup>	Mexican	ATS/ERS/JRS/ALAT guidelines 2011	373	168	103/65	64.5±11.0	205	36/69	47.0±5.4	<i>HSPA1B</i>	rs1061581	AA vs AG+GG	0.27 (0.13-0.57)	0.0003	5' nuclease SNP genotyping assays (PCR)	-
											<i>HSPA1A</i>	rs1043618	GG vs GC+CC	0.63 (0.41-0.97)	0.039		0.481
											<i>HSPA1L</i>	rs2227956	G	0.27 (0.10-0.75)	0.01		0.122
												rs2075800	CC vs TT	2.52 (1.32-4.81)	0.005		0.255
19	Peljto et al. (2015) <sup>19</sup>	Mexican	ATS/ERS/JRS/ALAT guidelines 2011	194	83	59/24	66.0±7.7	111	-	-	<i>LRRC34</i>	rs6793295	C	2.24	0.01	-	0.421
											<i>FAM13A</i>	rs2609255	G	2.09	0.02		0.348
											<i>TERT</i>	rs2736100	C	0.50	0.05		0.484
											<i>MUC5B</i>	rs35705950	T	7.36	1.1 × 10 <sup>-4</sup>		0.046

											<i>TOLLIP</i>	rs111521887	G	3.79	0.01		-
											<i>IVD</i>	rs2034650	G	0.40	0.01		0.491
		Korean		326	239	181/60	65.1±7.7	87	-	-	<i>IVD</i>	rs2034650	G	0.13	8.1×10 <sup>-4</sup>		0.491
20	Zhang et al. (2015) <sup>20</sup>	Han Chinese	ATS/ERS/JRS/ALAT guidelines 2011	368	102	45/57	59.3±9.87	266	137/129	56.7±12.80	<i>HLA-DRB1</i>	DRB1*08	DRB1*08	0.43 (0.19-0.96)	0.035	High resolution melting (HRM) method	-
											<i>IL-10</i>	rs1800896	G	1.80 (0.99-3.26)	0.05		0.272
21	Zhang et al. (2015) <sup>21</sup>	Chinese	ATS/ERS/JRS/ALAT guidelines 2013	215	115	67/48	58.1±11.4	100	55/45	57.2±5.5	<i>MMP-9</i>	rs3918242	T	1.62 (1.040-2.536)	0.034	PCR-RFLP	0.155
22	Horimasu et al. (2015) <sup>22</sup>	Japanese	ATS/ERS criteria 2002	354	44	35/9	67.5±1.6	310	255/55	50.6±0.4	<i>MUC5B</i>	rs35705950	T	4.34 (1.02-18.49)	0.031	PCR	0.046
		German		106	71	51/20	67.6±1.2	35	15/20	44.3±2.3	<i>MUC5B</i>	rs35705950	T	11.05 (3.30-36.99)	<0.001		0.046
23	Mathai et al. (2015) <sup>23</sup>	American	ATS/ERS/JRS/ALAT guidelines 2011	458	230	159/71	65.4 (64.2-66.5)	228	151/79	64.5 (63.7-65.4)	<i>DSP</i>	rs72825047	G	0.4 (0.19-0.85)~	0.0007	Illumina HiSeq platform	0.037
												rs72825054	C	0.4 (0.19-0.85)~	0.0003		0.037
												rs72825058	T	0.40 (0.17-0.78)~	0.0005		0.038
												rs874646	G	0.60 (0.34-0.89)~	0.002		0.256
												rs2744362	C	0.60 (0.34-0.89)~	0.002		0.256
												rs2008748	T	0.60 (0.34-0.89)~	0.001		0.745
												rs2744365	G	0.60 (0.34-0.89)~	0.002		0.230
												rs2237102	C	0.60 (0.34-0.89)~	0.002		0.245
												rs2237103	G	0.60 (0.34-0.89)~	0.002		0.250
												rs2237104	T	0.60 (0.34-0.89)~	0.002		0.246

												rs2078438	A	0.60 (0.34-0.89)~	0.002		0.230
												rs2744368	T	0.60 (0.34-0.89)~	0.002		0.233
												rs2744369	T	0.60 (0.34-0.89)~	0.001		0.234
												rs2744370	C	0.60 (0.34-0.89)~	0.002		0.236
												rs2744371	C	0.60 (0.34-0.89)~	0.002		0.234
												rs2744372	G	0.60 (0.34-0.89)~	0.002		0.249
												rs2744374	T	0.60 (0.34-0.89)~	0.002		0.250
												rs2744373	A	0.50 (0.34-1.04)~	0.004		0.108
												rs2744375	T	0.50 (0.34-1.04)~	0.004		0.146
												rs17133512	A (insertion)	1.70 (1.05-2.96)~	0.004		0.199
												rs145125286	C (deletion)	0.50 (0.34-1.04)~	0.003		0.116
												rs2008756	G	0.60 (0.34-0.89)~	0.0009		0.246
												rs2237105	A	0.60 (0.34-0.89)~	0.002		0.230
				1872	936	647/289	64.9 (64.34-65.60)	936	653/283	62.7 (62.23-63.24)	DSP	rs2744371	C	0.77 (0.66-0.91)	0.002	TaqMan genotyping assays	0.234
												rs2744373	A	0.80 (0.66-0.98)	0.03		0.108
												rs2076295/6p24	G	1.36 (1.19-1.56)	<0.001		0.432
24	Jiang et al. (2015) <sup>24</sup>	Han Chinese	ATS/ERS criteria 2002	437	187	138/49	69.7±4.3	250	172/78	67.7±7.3	MUC5B	rs35705950	T	1.93 (1.32-2.82)	0.0007	TaqMan probe-based SNP genotyping	0.046
25	Wang et al. (2014) <sup>25</sup>	Chinese	ATS/ERS/JRS/ALAT guidelines 2011	1178	165	101/64	61.8±12.72	1013	525/488	58.6±12.72	MUC5B	rs35705950	T	4.33 (1.99-9.42)	0.001	PCR-RFLP and TaqMan probe-based SNP genotyping	0.046
				485	80 (male and	-	-	405 (male and	-	-	MUC5B	rs35705950	T	10.48 (2.60-42.36)	0.001		0.046



					>=55 y)			>=55 y)									
26	Uh et al. (2014) <sup>26</sup>	Korean	ATS/ERS guidelines 2002	420	237	163/74	62.0(31-83)	183	55/128	61.0(50-81)	<i>ADAM33</i>	rs628977	AA vs AG+GG	0.50 (0.27-0.94)	0.03	Single-Base Extension (SBE)	0.341
				345	162	112/50	59.0(31-83)	183	55/128	61.0(50-81)	<i>ADAM33</i>	rs628977	AA vs AG+GG	0.40 (0.19-0.84)	0.02		0.341
27	Sangiolo et al. (2014) <sup>27</sup>	Italian	ATS/ERS/JRS/AL AT guidelines 2011	196	89	67/22	68.8±7.6	107	105/2	54.3±4.3	<i>HFE</i>	rs1799945*	GC	2.60 (1.35-5.02)	0.004**	reverse dot blot	0.073
28	Coghlan et al. (2014) <sup>28</sup>	Mixed, European (90% Caucasian, 5% African-American, 3% Asian and 2% Hispanic)	ATS/ERS/JRS/AL AT guidelines 2011	324	132	98/34	54.6±9.2	192	99/93	60.2±8.1	<i>MUC5B</i>	rs35705950	T	2.67 (1.78-4.01)	<0.0001	NGS	0.046
29	Ohshimo et al. (2014) <sup>29</sup>	German	-	127	42	-	-	85	-	-	<i>ANGPT2</i>	rs2515475	T	-	0.048	RT-PCR	0.0132
30	Fingerlin et al. (2013) <sup>G 30</sup>	non-hispanic white	ATS/ERS guidelines 2002	6299 <sub>D</sub>	1616	1090/526	65.5±9.5	4683	2289/2394	-	<i>TERT</i>	rs2736100	C	0.73 (0.67-0.79)	7.60 × 10 <sup>-14</sup>	Illumina Human 660W Quad BeadChip	0.484
											<i>DSP</i>	rs2076295	G	1.43 (1.32-1.55)	1.14 × 10 <sup>-16</sup>		0.432
											-	rs4727443	A	1.30 (1.20-1.41)	6.72 × 10 <sup>-9</sup>		0.381
											<i>MUC2</i>	rs7934606	C	1.52 (1.40-1.65)	5.46 × 10 <sup>-22</sup>		0.380 “
											-	rs2034650	G	0.77 (0.71-0.84)	1.86 × 10 <sup>-9</sup>		0.491
											<i>MAPT</i>	rs1981997	A	0.71 (0.64-0.78)	2.52 × 10 <sup>-8</sup>		0.087
											<i>DPP9</i>	rs12610495	G	1.29 (1.18-1.41)	9.57 × 10 <sup>-9</sup>		0.183
											-	rs3778337	A	1.31(1.20-1.43)	6.41 × 10 <sup>-9</sup>		0.303
											-	rs1379326	C	1.78 (1.45-2.19)	5.74 × 10 <sup>-9</sup>		0.329

										-	rs7942850	C	1.38 (1.27-1.50)	$9.29 \times 10^{-14}$		0.315
										-	rs6421972	T	1.51 (1.39-1.64)	$1.62 \times 10^{-21}$		0.390
										-	rs7480563	C	0.69 (0.64-0.75)	$4.17 \times 10^{-18}$		0.697
										-	rs4077759	C	0.74 (0.67-0.80)	$8.47 \times 10^{-13}$		0.484
										-	rs868903	T	0.64 (0.59-0.70)	$1.26 \times 10^{-22}$		0.510
										-	rs2334659	A	0.71 (0.63-0.80)	$4.71 \times 10^{-9}$		0.061
										-	rs7122936	C	0.76 (0.69-0.82)	$3.69 \times 10^{-8}$		0.346
										-	rs1992272	T	0.78 (0.71-0.85)	$3.49 \times 10^{-8}$		0.271
										-	rs1756398 6	G	0.71 (0.64-0.78)	$3.39 \times 10^{-8}$		0.086
										-	rs807023	G	0.71 (0.64-0.79)	$1.22 \times 10^{-8}$		0.773
										-	rs2109069	A	1.28 (1.18-1.40)	$3.87 \times 10^{-8}$		0.211
	2766 R	876	599/27 7	63.4±9.7	189 0	907/ 983	58.4±9 .7			<i>TERT</i>	rs2736100	C	0.74 (0.65-0.83)	$4.05 \times 10^{-7}$	Multiplex (Sequenom) iPLEX and uniplex (TaqMan) assays	0.484
										<i>DSP</i>	rs2076295	T	1.26 (1.13-1.42)	$6.28 \times 10^{-5}$		0.432
										<i>MUC2</i>	rs7934606	C	1.56 (1.39-1.76)	$1.49 \times 10^{-13}$		0.380 “
										-	rs2034650	G	0.82 (0.74-0.93)	0.00098		0.491
										<i>MAPT</i>	rs1981997	A	0.67 (0.58-0.79)	$4.74 \times 10^{-7}$		0.087
										<i>DPP9</i>	rs1261049 5	G	1.30 (1.15-1.47)	$3.94 \times 10^{-5}$		0.183
	9065 M	249 2	168 9/80 3	-	657 3	3196 /337 7	-			<i>TERT</i>	rs2736100	C	-	$1.71 \times 10^{-19}$		0.503
										<i>DSP</i>	rs2076295	T	-	$1.08 \times 10^{-19}$		0.432
										-	rs4727443	A	-	$1.17 \times 10^{-8}$		0.381
										<i>MUC2</i>	rs7934606	C	-	$6.87 \times 10^{-34}$		0.38 “
										-	rs2034650	G	-	$9.76 \times 10^{-12}$		0.491
										<i>MAPT</i>	rs1981997	A	-	$8.87 \times 10^{-14}$		0.087
										<i>DPP9</i>	rs1261049 5	G	-	$1.68 \times 10^{-12}$	0.183	

											<i>LRRC34</i>	rs6793295	C	-	$8.33 \times 10^{-13}$		0.421
											<i>FAM13A</i>	rs2609255	G	-	$2.20 \times 10^{-11}$		0.348
											<i>OBFC1</i>	rs11191865	A	-	$2.44 \times 10^{-8}$		0.397
											<i>ATP11A</i>	rs1278769	A	-	$6.72 \times 10^{-9}$		0.233
				3625	1735	-	-	1890	-	-	<i>MUC5B</i>	rs35705950	T	4.51 (3.91-5.21)	$7.21 \times 10^{-95}$		0.046
31	Noth et al. (2013) <sub>G31</sub>	European - American (617) and non-European - American (16)	ATS/ERS guidelines 2000 and ATS/ERS/JRS/ALAT guidelines 2011	1084 <sub>D</sub>	542	385/157	67.0(61-73)	542	-	63.0(40-70)	<i>SLC35F3</i>	rs11810452	G	-	$6.31 \times 10^{-6}$	Genome-Wide Human SNP 6.0 Array	0.230
												rs12750467	A	1.55 (1.25-1.93)	$6.31 \times 10^{-5}$		0.071
											<i>ARHGEF4</i>	rs13034562	G	-	$6.31 \times 10^{-5}$		0.555
												rs66525751	A	1.79 (1.36-2.35)	$7.94 \times 10^{-6}$		0.064
											<i>ABCG2</i>	chr4:89147344	-	7.36 (2.37-22.9)	$1.58 \times 10^{-6}$		-
											-	rs10065111	T	1.57 (1.28-1.93)	$1.58 \times 10^{-5}$		0.196
											-	rs7449198	A	1.65 (1.33-2.04)	$1.26 \times 10^{-6}$		0.132
											-	rs58608739	A	0.32 (0.18-0.56)	$6.31 \times 10^{-6}$		0.144
											-	rs6862667	G	0.32 (0.17-0.59)	$7.94 \times 10^{-5}$		0.208
											<i>MAD1L1</i>	rs55948146	G	0.66 (0.79-0.55)	$2.00 \times 10^{-6}$		0.437
												rs6977733	A	0.67 (0.56-0.80)	$1.00 \times 10^{-5}$		0.315
												rs3800917	A	0.67 (0.56-0.08)	$7.94 \times 10^{-6}$		0.302
											<i>K03193</i>	rs76795398	G	2.36 (1.54-3.63)	$1.00 \times 10^{-5}$		0.014
												rs79842896	C	2.49 (1.61-3.85)	$7.94 \times 10^{-6}$		0.014
											-	rs113172295	T	-	$7.94 \times 10^{-6}$		0.054
											<i>COLIA2</i>	rs2293739	A	0.63 (0.48-0.82)	$3.98 \times 10^{-4}$		0.063
<i>MYOM2</i>	rs17751471	A	1.56 (1.24-1.97)	$2.51 \times 10^{-5}$	0.105												
	rs6558599	G	1.87 (2.48-1.41)	$7.94 \times 10^{-6}$	0.112 “												

<i>PPP2R2A</i>	rs1425735	A	1.45 (1.76-1.20)	$1.00 \times 10^{-4}$	0.470
<i>LRP12</i>	rs4291236	C	1.78 (2.45-1.30)	$1.58 \times 10^{-4}$	0.029
	rs4537272	C	-	$2.00 \times 10^{-6}$	0.017
-	rs13802044 3*/ chr9:25356216	T	10.27 (2.24-46.6)	$7.94 \times 10^{-6}$	0.003
-	rs15104577 8*/ chr9:25370576	T	-	$1.26 \times 10^{-5}$	0.004
<i>MUC5B</i>	rs35705950	T	1.57 (1.20-2.05)	$6.31 \times 10^{-6}$	0.046
-	rs11041133	G	0.81 (0.96-0.68)	$1.00 \times 10^{-2}$	0.524
-	rs7481967	C	0.98 (1.25-0.77)	$7.94 \times 10^{-1}$	0.324
<i>TOLLIP</i>	rs5744033	G	-	$1.26 \times 10^{-6}$	0.927
	rs3168046	C	1.24 (1.05-1.47)	$1.00 \times 10^{-2}$	0.563
	rs3829223	C	0.83 (0.99-0.70)	$2.51 \times 10^{-2}$	0.501
	rs3750920	T	1.25 (1.06-1.48)	$5.01 \times 10^{-3}$	0.360
	rs5743961	A	0.82 (0.55-1.21)	$2.51 \times 10^{-1}$	0.048
	rs111521887	G	1.54 (1.26-1.87)	$5.01 \times 10^{-7}$	0.072
	rs908225	T	0.75 (0.91-0.62)	$2.51 \times 10^{-3}$	0.376
	rs5743944	A	0.69 (0.56-0.85)	$1.58 \times 10^{-4}$	0.148
	rs5743942	C	0.88 (0.75-1.05)	$1.00 \times 10^{-1}$	0.338
	rs5743905	C	0.82 (0.55-1.21)	$2.51 \times 10^{-1}$	0.047
	rs5743900	G	0.69 (0.55-0.86)	$3.16 \times 10^{-4}$	0.930
	rs5743899	G	0.90 (1.12-0.72)	$3.16 \times 10^{-1}$	0.339
	rs5743894	G	1.58 (1.30-1.93)	$1.26 \times 10^{-7}$	0.074

										rs117572864	T	1.11 (0.73-1.69)	$6.31 \times 10^{-1}$		0.024
										rs5743890	G	0.68 (0.53-0.88)	$2.51 \times 10^{-3}$		0.047
										rs4963062	A	1.09 (1.52-0.77)	$6.31 \times 10^{-1}$		0.210
									-	rs75735056	A	-	$2.00 \times 10^{-8}$		0.256
									MDGA2	rs4898572	A	1.89 (2.52-1.42)	$1.00 \times 10^{-5}$		0.035
										rs7144383	G	1.82 (1.37-2.41)	$2.00 \times 10^{-5}$		0.038
									-	rs573297762*/chr15:40693273	G	-	$2.51 \times 10^{-7}$		0.000
									IVD	rs1001528	A	0.65 (0.77-0.55)	$1.00 \times 10^{-6}$		0.493
									IQCH	rs17232873	G	2.16 (1.47-3.19)	$6.31 \times 10^{-5}$		0.065
									MAP2K5	rs12905544	T	2.53 (1.69-3.77)	$1.00 \times 10^{-6}$		0.025
									SPPL2C, MAPT-ASI	rs17690703	T	0.62 (0.51-0.76)	$5.01 \times 10^{-6}$		0.123
									-	rs78795069	C	0.52 (0.34-0.80)	$5.01 \times 10^{-4}$		0.023
									-	rs721597	C	1.44 (1.21-1.70)	$6.31 \times 10^{-6}$		0.373
European - American	1231 <sub>R</sub>	544	262/108	65.0(59-70)	687	393/294	56.0(46-65)		MUC5B	rs35705950	T	3.72 (3.02-4.58)	$2.50 \times 10^{-40}$	iPLEX Gold™ platform	0.046
									TOLLIP	rs111521887	G	1.58 (1.29-1.94)	$7.90 \times 10^{-6}$		0.072
										rs5743894	G	1.52 (1.25-1.86)	$1.60 \times 10^{-5}$		0.074
										rs5743890	G	0.57 (0.44-0.73)	$4.00 \times 10^{-6}$		0.047
										MDGA2	rs7144383	G	1.57 (1.18-2.08)		$1.00 \times 10^{-3}$
									SPPL2C, MAPT-ASI	rs17690703	T	0.74 (0.61-0.89)	$1.60 \times 10^{-3}$		0.123
European - American	1026 <sub>R</sub>	324	68/22	68.0(63-72)	702	497/205	62.0(55-68)		MUC5B	rs35705950	T	3.08 (2.37-3.99)	$5.14 \times 10^{-16}$	0.046	
									TOLLIP	rs111521887	G	1.24 (0.98-1.50)	$8.03 \times 10^{-2}$	0.072	

											<i>TOLLIP</i>	rs5743894	G	1.19 (0.94-1.50)	$1.57 \times 10^{-1}$		0.074
											<i>TOLLIP</i>	rs5743890	G	0.60 (0.45-0.80)	$3.49 \times 10^{-4}$		0.047
											<i>SPPL2C</i>	rs17690703	T	0.78 (0.62-0.98)	$3.07 \times 10^{-2}$		0.123
32	Uh et al. (2013) <sup>32</sup>	Korean	ATS/ERS guidelines 2002	676	220	153/67	62.0(50-83)	456	278/178	63.0(50-87)	ACE	rs4277405	CC vs CT+TT	2.16 (1.35-3.45)	0.001	Single base extension (SBE)	0.354
												rs4459609	CC vs CA+AA	2.09 (1.30-3.38)	0.003		0.353
												rs1800764	CC vs CT+TT	1.93 (1.21-3.07)	0.006		0.533
												rs4291	TT vs AT+AA	1.72 (1.07-2.78)	0.03		0.348
												rs4292	CC vs CT+TT	1.86 (1.16-2.98)	0.01		0.256
												rs4309	CC vs CT+TT	1.72 (1.09-2.71)	0.02		0.576
												rs4311	TT vs CT+CC	1.74 (1.06-2.85)	0.03		0.334
												rs4343	GG vs GA+AA	1.73 (1.07-2.79)	0.03		0.356
												rs4351	GG vs AG+AA	1.86 (1.16-2.99)	0.01		0.439
				rs1055086	AA vs AG+GG	1.69 (1.10-2.59)	0.02	0.342									
				(+)21288_insdel	-	1.84 (1.18-2.86)	0.008	-									
				rs4277405	CC vs CT+TT	2.00 (1.31-3.06)	0.001	0.354									
				rs4459609	CC vs CA+AA	1.97 (1.28-3.04)	0.002	0.353									
				rs1800764	CC vs CT+TT	1.83 (1.20-2.77)	0.005	0.533									
				rs4291	TT vs AT+AA	1.66 (1.08-2.56)	0.02	0.348									
				rs4292	CC vs CT+TT	1.79 (1.17-2.74)	0.007	0.256									
				rs4309	CC vs CT+TT	1.71 (1.14-2.58)	0.01	0.576									
				rs4311	TT vs CT+CC	1.78 (1.15-2.78)	0.01	0.334									
				rs4343	GG vs GA+AA	1.70 (1.10-2.62)	0.02	0.356									
				607	151 (surgical IPF)	105/46	59.0(50-83)	456	278/178	63.0(50-87)							

												rs4351	GG vs AG+AA	1.81 (1.19-2.76)	0.006		0.439
												rs1055086	AA vs AG+GG	1.68 (1.15-2.46)	0.007		0.342
												(+)21288_insdel	-	1.62 (1.08-2.43)	0.02		-
33	Wei et al. (2013) <sup>33</sup>	American whites	ATS/ERS guidelines 2002	773	84	55/29	64.4±7.7	689	360/329	55.7±13.2	<i>MUC5B</i>	rs35705950	T	3.20 (2.21-4.63)	1.16 × 10 <sup>-10</sup>	TaqMan SNP genotyping assay (PCR)	0.046
34	Stock et al. (2013) <sup>34</sup>	UK Caucasian	ATS/ERS criteria 2000 and ATS/ERS guidelines 2002	526	110	79/31	64.6(45-85)	416	-	-	<i>MUC5B</i>	rs35705950	T	4.90 (3.42-7.03)	2.04×10 <sup>-17</sup>	TaqMan SNP genotyping assay (PCR)	0.046
35	Borie et al. (2013) <sup>35</sup>	Caucasian (European-82%; North African-14%; Black-4%)	ATS/ERS guidelines 2000	1525	142	116/26	69.8±8.9	1383	-	-	<i>MUC5B</i>	rs35705950	T	5.19 (3.56-7.58)~	2.0×10 <sup>-44</sup>	TaqMan SNP genotyping assay (PCR)	0.046
36	Son et al. (2013) <sup>36</sup>	Korean	ATS/ERS guidelines 2002	170	85 surgical IPF	55/30	61.0±8	85	55/30	59.0±8	<i>TGF-β1</i>	rs1800470	TT vs TC+CC	2.10 (1.1-4.0)	0.028	PCR-RFLP	0.540
37	Martinielli et al. (2013) <sup>37</sup>	Italian	ATS/ERS/JRS/ALAT guidelines 2011	113	32	17/13	68.2±9.7	81	43/38	68.0±12.6	<i>TCN2</i>	rs1801198	G	1.83 (1.02-3.29)	0.04	PCR-RFLP	0.420
38	Yadong et al. (2013)	Chinese	-	184	84	-	-	100	-	-	<i>ACE</i>	insertion/deletion polymorphism	Deletion	-	<0.05	PCR-RFLP	-
39	Korthagen et al. (2012) <sup>38</sup>	Netherlands	ATS/ERS criteria 2002	430	77	58/19	60.8±13.6	353	139/210	39.2±12.4	<i>CDKN1A</i>	rs2395655	G	1.61 (1.13-2.28)~	0.007~	Illumina GoldenGate bead SNP assay	0.527
												rs733590	C	1.52 (1.07-2.17)~	0.01~		0.406
												rs730506	C	1.52 (1.03-2.24)~	0.032~		0.218
												rs3176352	C	0.60 (0.41-0.87)~	0.007~		0.496

40	Zhang et al. (2012) <sup>39</sup>	Han Chinese	ATS/ERS criteria 2000	11,991	36	24/12	63.4±5.1	11955	8129/3826	48.3±12.1	HLA-A	HLA-A*03	HLA-A*03	-	0.002	PCR-SSP	-
											HLA-B	HLA-B*14	HLA-B*14	-	<0.0001		-
												HLA-B*15	HLA-B*15	-	<0.0001		-
				HLA-B*40	HLA-B*40	-	<0.0001	-									
				11,986	31	-	-	11,955	-	-	HLA-A	HLA-A*03	HLA-A*03	-	0.0013		-
											HLA-B	HLA-B*15	HLA-B*15	-	<0.0001		-
HLA-B*40	HLA-B*40	-	<0.0001									-					
41	Zhang et al. (2011) <sup>40</sup>	Non-Hispanic Whites	ATS/ERS criteria 2002**	412	246	163/83	67.4±9.0	166	71/95	48.7±16.1	MUC5B	rs35705950	T	4.18 (2.82-6.20)	<0.0001	TaqMan SNP genotyping assay (PCR)	0.046
		Non-Hispanic Whites		731	95	75/20	69.2±8.4	636	365/271	53.7±14.1	MUC5B	rs35705950	T	4.43 (3.14-6.25)	<0.0001		0.046
42	Ahn et al. (2011) <sup>41</sup>	Korean	ATS/ERS criteria 2000	618	237	163/74	61.0(41-83)~	456	278/178	62.0(50-87)	IL8	rs4073	AA vs AT+TT	0.46 (0.26-0.80)	0.006	TaqMan SNP genotyping assay (PCR)	0.522
											IL8	rs2227307	GG vs GT+TT	0.48 (0.28-0.82)	0.007		0.423
				330	152 (males)	-	-	178 (males)	-	-	IL8	rs4073	AA vs AT+TT	0.51 (0.26-0.97)	0.04		0.522
											IL8	rs2227307	GG vs GT+TT	0.49 (0.26-0.93)	0.03		0.423
43	Seibold et al. (2011) <sup>42</sup>	Caucasian	ATS/ERS criteria 2000 and ATS/ERS guidelines 2002	814	492	352/140	67.2±8.1	322	147/175	60.3±12.6	MUC2	rs10902081	TT vs CC	0.70 (0.5-0.8)	4.3 × 10 <sup>-4</sup>	Sequenom iPLEX assay	0.450 “
												rs41453346	TT vs CC	2.80 (1.6-5.2)	0.001		0.008
												rs41480348	AA vs GG	0.50 (0.4-0.8)	0.001		0.031
											-	rs9667239	TT vs CC	1.90 (1.4-2.7)	5.6 × 10 <sup>-4</sup>		0.101
											MUC5AC	rs55846509	AA vs GG	3.60 (1.7-7.3)	0.001		0.007
												rs28403537	TT vs CC	4.60 (2.8-7.6)	3.2 × 10 <sup>-9</sup>		0.059 “
												rs35288961	TT vs GG	2.00 (1.5-2.6)	3.7 × 10 <sup>-6</sup>		0.100
												-	rs35671223	TT vs CC	1.50 (1.2-1.9)		0.001



											-	rs2865423 2	TT vs CC	0.60 (0.5-0.8)	$1.1 \times 10^{-4}$		0.375	
											<i>MUC5B</i>	rs2672794	TT vs CC	0.50 (0.4-0.7)	$1.9 \times 10^{-7}$		0.313	
											<i>MUC5B</i>	rs3570595 0	TT vs GG	8.30 (5.8-11.9)	$4.6 \times 10^{-31}$		0.046	
											<i>MUC5B</i>	rs1280400 4	TT vs GG	0.60 (0.5-0.8)	$1.2 \times 10^{-4}$		0.560	
							304	-	-		<i>MUC5B</i>	rs3561954 3	TT vs GG	2.10 (1.6-2.8)	$1.5 \times 10^{-8}$		0.226	
											<i>MUC5B</i>	rs868903	CC vs TT	1.60 (1.3-2.1)	$2.8 \times 10^{-5}$		0.489	
											<i>MUC5AC</i>	MUC5AC- 025447	TT vs CC	1.60 (1.2-2.2)	0.003		-	
											<i>MUC2</i>	rs7934606	TT vs CC	1.70 (1.4-2.2)	$3.8 \times 10^{-6}$		0.380 “	
											<i>MUC2</i>	rs1090208 9	GG vs AA	1.50 (1.2-1.9)	$2.9 \times 10^{-4}$		0.492 “	
											<i>MUC2</i>	rs7127117	CC vs TT	1.60 (1.3-2.0)	$6.9 \times 10^{-5}$		0.520	
											-	rs3459590 3	TT vs CC	0.50 (0.4-0.7)	$2.4 \times 10^{-6}$		0.267	
				150	96	61/3 5	65.0±8	54	18/3 6	68.0±8		<i>MUC2</i>	rs3436734 8	A	0.60 (0.3-1.0)	<0.05	PCR followed by cycle sequencing reactions at 1/64 Big Dye reaction scale	0.031
											<i>MUC2</i>	rs7104590	C	0.50 (0.3-0.9)	<0.05	0.357 “		
											<i>MUC2</i>	rs1090208 1	T	1.70 (1.0-2.9)	<0.05	0.450 “		
											<i>MUC2</i>	rs1241687 3	A	0.40 (0.2-0.8)	<0.01	0.361		
											<i>MUC5AC</i>	MUC5AC- 022675	T	4.60 (1.0-42.6)	<0.05	-		
											<i>MUC5AC</i>	MUC5AC- 026495	C	0.50 (0.2-1.0)	<0.05	-		
											<i>MUC5AC</i>	rs3528896 1	T	2.30 (1.2-4.8)	<0.01	0.100		
44	Xue et al. (2011) <sub>43</sub>	Caucasian	ATS/ERS criteria 2000	560	275	73/202	66.0±1	285	-	-	<i>HLA-DRB1</i>	HLA-DRB1*1501	HLA-DRB1*1501	1.85 (1.31-2.62)~	0.0005~	PCR-SSP	-	
45	Barlo et al. (2011) <sub>44</sub>	Caucasian	ATS/ERS criteria 2002	426	77	58/19	60.8±13.6	349	139/210	39.2±12.4	<i>ILIRN</i>	rs2637988	G	1.94 (1.11-3.41)	0.02	Illumina GoldenGate bead SNP assay	0.517	
46	Xinxia et	Han Chinese		170	85	68/17	62.4±9.5	85	68/17	61.9±9.4	<i>TGF-β1</i>	rs1800470	CC vs CT	1.96 (1.06-3.64)	0.0312	PCR-RFLP	0.460	

	al. (2011) 45		ATS/ERS criteria 2000								<i>PAI-1</i>	PAI-1 4G/5G	5G5G vs 4G5G+4 G4G	0.42 (0.19- 0.90)	0.02		-
47	Yuan et al. (2011) 46	Chinese	-	118	64	-	-	54	-	-	<i>CRI</i>	HindIII RFLP (intron 27)	L	4.47 (2.37- 8.44)	<0.05	PCR-RFLP	-
48	Bourna zos et al. (2010) 47	Caucasia n	BTS/Thor acic society of Australia/ New Zealand and the Irish Thoracic Society Interstitial lung disease guideline 2008	363	142	95/4 7	70.0±8.8	221	-	71.4±10 .2	<i>FCGR3B</i>	>2 FCGR3B copies	-	1.91 (1.17- 3.12)	0.01	RT-PCR	-
49	Aquin o- Gálvez et al. (2009) 48	Mexican	ATS/ERS criteria 2000	281	80	42/3 8	64.8±11.0	201	72/1 29	53.4±1 1.2	<i>MICA</i>	MICA*00 1	MICA* 001	2.91 (1.04- 8.25)	0.03**	Reference strand mediated conformation analysis (RSCA)	-
											MICA*00 4	MICA* 004	0.41 (0.20- 0.80)	0.008**	-		
											MICA*00 4/*004	MICA* 004/*00 4	0.17 (0.0 – 1.15)	0.04**	-		
											MICA*00 1/*00201	MICA* 001/*00 201	4.72 (1.15- 22.51)	0.01**	-		
50	Liu et al. (2009) 49	Chinese	-	120	60	-	-	60	-	-	<i>ENA-78</i>	156G/C	C	4.23 (1.35- 13.20)	0.008	PCR-RFLP	-
											<i>IP-10</i>	1596C/T	T	0.38 (0.15- 0.95)	0.031		-
51	Mushir oda et al. (2008) G50	Japanese	ATS/ERS guideline s 2002	1711	242	183/ 59	67.0(42- 87)	1,46 9	948/ 521	-	<i>TERT</i>	rs2736100	A	1.81 (1.46- 2.23)*	2.9 × 10 <sup>-8</sup>	Illumina HumanHap30 0 Bead Arrays and multiplex- PCR based Invader	0.496

																assay3 or TaqMan assay	
52	Checa et al. (2008) <sup>51</sup>	Mexican	ATS/ERS criteria 2000	435	130	67/63	62.5±9.6	305	189/116	40.6±12.4	<i>MMP-1</i>	1G_1607_2G	2G	1.61 (1.13-2.29)	0.0074~/0.006**	PCR-RFLP	-
				156	49 (smokers)	-	-	107 (smokers)	-	-	<i>MMP-1</i>	G755T	T	1.68 (1.01-2.74)	0.048~/0.04**		-
53	Vasakova et al. (2006) <sup>52</sup>	Caucasian of Czech Republic	ATS/ERS criteria 2000	133	30	10/20	65.4(36-85)	103	24/79	53.0(24-71)	<i>IL-4</i>	C33T	T	3.35 (1.74-6.44)~	0.0003~	PCR	-
											<i>IL-4</i>	rs2243250	T	0.19 (0.10-0.37)~	<0.0001~		0.469
54	Riha et al. (2004) <sup>53</sup>	Caucasian	ATS/ERS criteria 2000	162	22	17/5	60.0±14	140	-	-	<i>TNF-α</i>	A308G	A	3.29 (1.61-6.70)~	0.001	PCR-RFLP	-
55	Zorzetto et al. (2003) <sup>54</sup>	Italian whites	ATS/ERS criteria 2002	240	74	51/23	66.5±10.9	166	105/61	61.7±8.4	<i>CR1</i>	C5507G	G	2.38 (1.53-3.69)~	0.0001~	PCR-RFLP	-
											<i>CR1</i>	C5507G	CC	0.45 (0.25-0.78)	0.004		-
56	Selman et al. (2003) <sup>55</sup>	Mexican	ATS/ERS criteria 2000	248	54(non smokers)	-	-	194	124/70	41.0±14.5	<i>SP-A1</i>	SP-A1	6A <sup>4</sup>	3.67 (1.34-10.07)	0.01	PCR-RFLP	-
											<i>SP-A1</i>	SP-AA219	T	3.13 (1.18-8.32)	0.02		-
											<i>SP-A1</i>	SP-AA50	C	6.68 (1.87-23.86)	<0.01		-
											<i>SP-A1</i>	SP-AA62	G	3.34 (1.56-7.14)	<0.01		-
				124	30(smokers)	-	-	194	124/70	41.0±14.5	<i>SP-B</i>	SP-B1580	C	7.63 (1.64-35.4)	0.01		-
57	Libby et al. (1982) <sup>56</sup>	Caucasian	Patients evaluated with a medical history, physical examination, chest radiograph, pulmonary function tests, and lung biopsy.	220	20	11/9	57.2	200	-	-	<i>HLA-DR</i>	HLA-DR2	HLA-DR2	5.28 (2-13.96)~	0.0006	Two stage complement-dependent micro-lymphocytotoxicity assay	-

Legend: All studies include sporadic IPF cases only except Fingerlin et al., 2013<sup>30</sup> which include fibrotic IIPs as cases. In paper Allen et al., 2020<sup>3</sup>, sex data only available for 500 Chicago cases and 510 Chicago controls & age data available for 602 UK cases; in paper Allen et al., 2020<sup>3</sup> & 2017,<sup>12</sup> age data available for 103 Chicago controls; In paper Fingerlin et al., 2013,<sup>30</sup> p-value is adjusted for sex; in paper Noth et al., 2013,<sup>31</sup> sex data available for 370 & 90 cases in replication phase I & II respectively and age data is only available for 103 controls in discovery GWAS.

Global allele frequency of risk allele taken from dbSNP (1000 Genomes Project).<sup>57</sup>

OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; N, number; ATS, American Thoracic Society; ERS, European Respiratory Society; JRS, Japanese Respiratory Society; ALAT, Latin-American Thoracic association; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSP, sequence specific amplification.

ATS/ ERS guidelines 2000<sup>58</sup>

ATS/ERS guidelines 2002<sup>59</sup>

ATS/ERS criteria 2002\*\*<sup>60</sup>

ATS/ERS/JRS/ALAT guidelines 2011<sup>61</sup>

ATS/ERS guidelines 2013<sup>62</sup>

ATS/ERS/JRS/ALAT guidelines 2018<sup>63</sup>

BTS/Thoracic society of Australia/New Zealand and the Irish Thoracic Society Interstitial lung disease guideline 2008<sup>64</sup>

<sup>G</sup>Genome wide association study; <sup>D</sup>Discovery cohort; <sup>R</sup>Replication cohort, <sup>M</sup>Meta-analysis; ~ calculated value; \*\* corrected p-value; \* annotated rsid from dbSNP; <sup>α</sup> chicago consortium; <sup>β</sup> colorado consortium; <sup>γ</sup> UK biobank; @ UUS; ^ genentech, \* calculated value, “ allele frequency taken from ALFA.

**Supplementary Table 5:** Details of quality assessment scoring for studies included in the meta-analysis based on modified Newcastle Ottawa Scale (NOS).

SI. No	Included studies	Selection				Comparability		Exposure			Total star
		Adequate case definition	Representative samples of cases	Appropriate control selection	Controls are respiratory disease negative	Controls for Age	Controls for Gender	Assessment of outcome	Same method of ascertainment for cases and controls	Non-response rate	
<i>MUC5B</i>											
1	Bonella et al. (2021)	*	*	*	*	-	*	*	*	-	7
2	Deng et al. (2019)	*	-	*	*	*	*	*	*	-	7
3	Dressen et al. (2018)	*	*	*	-	*	*	*	*	-	7
4	Dabar et al. (2018)	*	-	*	-	-	-	-	-	-	2
5	Allen et al. (2017)	*	-	*	*	*	*	*	-	-	6
6	Petrovski et al. (2017)	*	*	*	*	-	-	*	*	-	6
7	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4
8	Van der Vis et al. (2015)	*	*	*	*	-	-	*	*	-	6
9	Horimasu et al. (2015)	*	*	*	*	-	-	*	*	-	6
10	Jiang et al. (2015)	*	*	*	*	*	*	*	*	-	8
11	Wang et al. (2014)	*	*	*	*	*	*	*	*	-	8
12	Coghlan et al. (2014)	*	*	*	-	*	-	*	-	-	5
13	Noth et al. (2013)	*	*	*	*	-	-	*	*	-	6
14	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
15	Wei et al. (2013)	*	*	*	*	-	-	*	*	-	6
16	Stock et al. (2013)	*	*	*	*	-	-	*	*	-	6
17	Borie et al. (2013)	*	*	*	-	-	-	*	*	-	5

18	Zhang et al. (2011)	*	*	*	*	-	-	*	*	-	6
<b>TERT</b>											
19	Guzmán-Vargas et al. (2021)	*	*	*	*	*	*	*	*	-	8
20	Arimura-Omori et al. (2020)	*	*	*	*	*	*	*	*	-	8
21	Dressen et al. (2018)	*	*	*	-	*	*	*	*	-	7
22	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4
23	Wei et al. (2013)	*	*	*	*	-	-	*	*	-	6
24	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
25	Mushiroda et al. (2008)	*	*	*	-	-	-	*	*	-	5
<b>FAM13A</b>											
26	Guzmán-Vargas et al. (2021)	*	*	*	*	*	*	*	*	-	8
27	Hirano et al. (2016)	*	*	*	*	-	-	*	*	-	6
28	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4
29	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
<b>DSP</b>											
30	Guzmán-Vargas et al. (2021)	*	*	*	*	*	*	*	*	-	8
31	Allen et al. (2017)	*	-	*	*	*	*	*	-	-	6
32	Noth et al. (2013)	*	*	*	*	-	-	*	*	-	6
33	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
<b>DPP9</b>											
34	Allen et al. (2017)	*	-	*	*	*	*	*	-	-	6
35	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4

36	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
<b><i>TGF-β1</i></b>											
37	Deng et al. (2019)	*	-	*	*	*	*	*	*	-	7
38	Zhang et al. (2015)	*	*	*	*	-	-	*	*	-	6
39	Son et al. (2013)	*	*	*	*	-	*	*	*	-	7
40	Alhamad et al. (2013)	*	*	*	*	-	-	*	*	-	6
41	Xin-xia et al. (2011)	*	*	*	*	*	*	*	*	-	8
42	Xaubet et al. (2003)	*	-	-	*	-	-	*	*	-	4

Legend: The modified Newcastle-Ottawa Scale (NOS) assesses the study quality in 3 categories: selection, comparability, and exposure. A maximum of 4 stars (\*) could be given to selection items, 2 stars to comparability section and 3 stars to Exposure category.

**Supplementary Table 6:** Summary of subgroup analysis findings based on ethnicity between IPF patients and healthy controls for genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), e) rs1800470 (*TGF-β1*).

SI. No.	Genetic variant (Gene)	Sub-group	Number of studies (N)	Heterogeneity		OR (95% CI)
				I <sup>2</sup> (%)	p-value	
1	rs35705950 ( <i>MUC5B</i> )	Asian	4	17.97	0.549	2.54 (0.78-4.31)
		European	14	81.93	0.00	3.97 (3.52-4.60)
2	rs2736100 ( <i>TERT</i> )	Asian	2	0.00	0.85	0.56 (0.46-0.65)
		European	5	0.00	0.08	0.74 (0.70-0.79)
3	rs2609255 ( <i>FAM13A</i> )	Asian	1	-	-	2.01 (1.22-2.80)
		European	3	16.35	0.31	1.36 (1.27-1.47)
4	rs1800470 ( <i>TGF-β1</i> )	Asian	4	57.32	0.025	1.07 (0.75-1.39)
		European	1	-	-	0.95 (0.62-1.29)
		Others	1	-	-	1.42 (0.79-2.06)

Legend: OR, Odds ratio; CI, Confidence interval; N, Number. All calculations were done using Stata/MP 16.0.

All p values calculated using chi-square test.

**Supplementary Table 7:** Sensitivity analysis with pooled odds ratios (OR) for studies exploring the association of genetic variants with IPF susceptibility by removing one study each time.


Genetic variant (Gene)	Study omitted (Author & Year)	OR (95% CI)	p-value	Heterogeneity		Model	Egger's test	
				I <sup>2</sup> (%)	p-value		Z-score	p-value
rs35705950 ( <i>MUC5B</i> )	Bonella et al. (2021)	3.83 (3.21-4.45)	<b>0.00</b>	82.68	0.00	R	1.38	0.17
	Deng et al. (2019)	3.85 (3.23-4.47)	<b>0.00</b>	82.64	0.00	R	1.58	0.11
	Dressen et al. (2018)	3.76 (3.13-4.40)	<b>0.00</b>	80.00	0.00	R	1.75	0.08
	Allen et al. (2017)	3.72 (3.11-4.32)	<b>0.00</b>	79.71	0.00	R	1.68	0.09
	Petrovski et al. (2017)	3.85 (3.20-4.50)	<b>0.00</b>	83.03	0.00	R	1.48	0.14
	Kishore et al. (2016)	3.81 (3.19-4.44)	<b>0.00</b>	82.63	0.00	R	1.35	0.18
	Van der Vis et al. (2015)	3.87 (3.22- 4.52)	<b>0.00</b>	83.12	0.00	R	1.49	0.13
	Horimasu et al. (2015) I	3.85 (3.23-4.47)	<b>0.00</b>	82.66	0.00	R	1.61	0.11
	Horimasu et al. (2015) II	3.84 (3.23-4.46)	<b>0.00</b>	82.58	0.00	R	1.26	0.21
	Jiang et al. (2015)	3.99 (3.38-4.59)	<b>0.00</b>	78.82	0.00	R	1.34	0.18
	Wang et al. (2014)	3.85 (3.22-4.47)	<b>0.00</b>	82.85	0.00	R	1.50	0.13
	Coghlan et al. (2014)	3.93 (3.29-4.57)	<b>0.00</b>	82.16	0.00	R	1.46	0.14
	Noth et al. (2013) I	4.01 (3.44-4.59)	<b>0.00</b>	72.91	0.00	R	1.14	0.26
	Noth et al. (2013) II	3.88 (3.22-4.54)	<b>0.00</b>	82.80	0.00	R	1.46	0.15
	Noth et al. (2013) III	3.93 (3.29-4.59)	<b>0.00</b>	81.82	0.00	R	1.41	0.16
	Fingerlin et al. (2013)	3.81 (3.15-4.46)	<b>0.00</b>	80.47	0.00	R	1.64	0.10
	Wei et al. (2013)	3.90 (3.25-4.55)	<b>0.00</b>	82.84	0.00	R	1.47	0.14
	Stock et al. (2013)	3.79 (3.16-4.42)	<b>0.00</b>	82.44	0.00	R	1.41	0.16
	Borie et al. (2013)	3.72 (3.13-4.31)	<b>0.00</b>	79.25	0.00	R	1.55	0.12
Zhang et al. (2011) I	3.84 (3.19-4.49)	<b>0.00</b>	83.04	0.00	R	1.47	0.14	
Zhang et al. (2011) II	3.82 (3.18-4.47)	<b>0.00</b>	82.88	0.00	R	1.46	0.14	
rs2736100 ( <i>TERT</i> )	Guzmán-Vargas et al. (2021)	0.72 (0.62-0.82)	<b>0.00</b>	72.31	0.00	R	1.91	0.06
	Arimura-Omori et al. (2020)	0.72 (0.62-0.82)	<b>0.00</b>	73.10	0.00	R	1.54	0.12
	Dressen et al. (2018)	0.70 (0.58-0.81)	<b>0.00</b>	73.14	0.00	R	1.74	0.08
	Kishore et al. (2016)	0.68 (0.60-0.76)	<b>0.00</b>	66.25	0.01	R	-0.06	0.95
	Wei et al. (2013)	0.68 (0.59-0.78)	<b>0.00</b>	69.84	0.00	R	1.06	0.29
	Fingerlin et al. (2013) I	0.70 (0.58-0.82)	<b>0.00</b>	75.36	0.00	R	1.65	0.09



	Fingerlin et al. (2013) II	0.69 (0.58-0.81)	<b>0.00</b>	76.59	0.00	R	1.55	0.12
	Mushiroda et al. (2008)	0.73 (0.68-0.77)	<b>0.00</b>	0.01	0.03	R	1.29	0.20
rs2609255 ( <i>FAM13A</i> )	Guzmán-Vargas et al. (2021)	1.36 (1.26-1.46)	<b>0.00</b>	44.55	0.14	F	0.81	0.42 $\beta$
	Kishore et al. (2016)	1.38 (1.28-1.48)	<b>0.00</b>	36.19	0.20	F	1.98	0.05
	Hirano et al. (2016)	1.36 (1.25-1.46)	<b>0.00</b>	16.35	0.31	F	0.27	0.79
	Fingerlin et al. (2013) I	1.45 (1.28-1.61)	<b>0.00</b>	36.97	0.19	F	0.60	0.55
	Fingerlin et al. (2013) II	1.33 (1.21-1.45)	<b>0.009</b>	38.45	0.18	F	1.12	0.26
rs2076295 ( <i>DSP</i> )	Guzmán-Vargas et al. (2021)	1.45 (1.28-1.63)	<b>0.00</b>	76.94	0.01	R	-0.18	0.86
	Allen et al. (2017)	1.23 (0.88-1.57)	<b>0.00</b>	93.00	0.00	R	-2.99	0.00
	Noth et al. (2013)	1.34 (0.94-1.74)	<b>0.00</b>	94.99	0.00	R	-1.71	0.09
	Fingerlin et al. (2013) I	1.28 (0.87-1.68)	<b>0.00</b>	93.21	0.00	R	-2.81	0.05
	Fingerlin et al. (2013) II	1.26 (0.86-1.65)	<b>0.00</b>	94.03	0.00	R	-1.64	0.10
rs12610495 ( <i>DPP9</i> )	Allen et al. (2017)	1.28 (1.19-1.36)	<b>0.00</b>	0.00	0.69	F	-0.25	0.80
	Kishore et al. (2016)	1.30 (1.22-1.38)	<b>0.00</b>	0.00	0.55	F	1.08	0.28
	Fingerlin et al. (2013) I	1.33 (1.22-1.45)	<b>0.00</b>	0.00	0.69	F	-0.72	0.47
	Fingerlin et al. (2013) II	1.28 (1.19-1.37)	<b>0.00</b>	0.00	0.15	F	-0.05	0.96
rs1800470 ( <i>TGF-<math>\beta</math>1</i> )	Deng et al. (2019)	0.96 (0.78-1.13)	<b>0.00</b>	41.66	0.14	F	2.11	0.03
	Zhang et al. (2015)	1.11 (0.78-1.445)	<b>0.00</b>	63.80	0.03	R	2.69	0.007
	Son et al. (2013)	1.04 (0.79 – 1.29)	<b>0.00</b>	61.20	0.04	R	2.40	0.02
	Alhamad et al. (2013)	1.03 (0.79-1.27)	<b>0.00</b>	59.01	0.05	R	2.30	0.02
	Xin-xia et al. (2011)	1.14 (0.95-1.33)	<b>0.00</b>	18.02	0.31	F	1.83	0.07
	Xaubet et al. (2003)	1.12 (0.83-1.41)	<b>0.00</b>	53.53	0.03	R	2.53	0.01

Legend: Bold characters highlight significantly associated alleles with respective p-values. OR, Odds ratio; CI, Confidence interval; R, Random effect model (maximum likelihood method); F, Fixed effect model (inverse-variance method); N, Number. All calculations were done using Stata/MP 16.0. All p values were calculated using the chi-square test.

**Supplementary Fig. 2:** Funnel plots showing publication bias among studies exploring IPF risk associated with genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), d) rs2076295 (*DSP*), e) rs12610495 (*DPP9*), f) rs1800470 (*TGF- $\beta$ 1*). Each point – represents a separate study for the indicated association or natural logarithm (log) of OR. A horizontal line means effect size.



## REFERENCES

1. Dhindsa RS, Mattsson J, Nag A, Wang Q, Wain LV, Allen R, et al. Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis. *Commun. Biol.* 2021; 4(1): 1-8.
2. Bonella F, Campo I, Zorzetto M, Boerner E, Ohshimo S, Theegarten D, et al. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. *Orphanet J. Rare Dis.* 2021; 16(1).
3. Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, et al. Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2020; 201(5): 564–74.
4. Arimura-Omori M, Kiyohara C, Yanagihara T, Yamamoto Y, Ogata-Suetsugu S, Harada E, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: Findings from the fukuoka tobacco-related lung disease (fold) registry. *Asian Pac. J. Cancer Prev.* 2020; 21(3): 667–73.
5. Moore C, Blumhagen RZ, Yang I v., Walts A, Powers J, Walker T, et al. Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2019; 200(2): 199–208.
6. Liu J, Deng Y, Wang Z, Mo B, Wei J, Cheng Z, et al. A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese. *J. Clin. Lab. Anal.* 2021; 35(6): e23782.
7. Deng Y, Li Z, Liu J, Wang Z, Cao Y, Mou Y, et al. Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis. *Hum. Mutat.* 2018; 39(9): 1238–45.
8. Wang H, Zhuang Y, Peng H, Cao M, Li Y, Xu Q, et al. The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort. *Sci. Rep.* 2019; 9(1): 1-7.
9. Lorenzo-Salazar JM, Ma SF, Jou J, Hou PC, Guillen-Guio B, Allen RJ, et al. Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing. *ERJ Open Res.* 2019; 5(2).

10. Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. *Lancet Respir. Med.* 2018; 6(8): 603–14.
11. Daniil Z, Kotsiou OS, Grammatikopoulos A, Peletidou S, Gkika H, Malli F, et al. Detection of mitochondrial transfer RNA (mt-tRNA) gene mutations in patients with idiopathic pulmonary fibrosis and sarcoidosis. *Mitochondrion.* 2018; 43: 43-52.
12. Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. *Lancet Respir. Med.* 2017; 5(11): 869–80.
13. Petrovski S, Todd JL, Durheim MT, Wang Q, Chien JW, Kelly FL, et al. An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis. *Am J Respir Crit Care Med.* 2017; 196(1): 82–93.
14. Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, et al. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. *Respir. Med.* 2017; 123: 105–9.
15. Yamaguchi K, Iwamoto H, Horimasu Y, Ohshimo S, Fujitaka K, Hamada H, et al. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. *Respirology.* 2017; 22(5): 965-71.
16. Kishore A, Žižková V, Kocourková L, Petrková J, Bouros E, Nunes H, et al. Association study for 26 candidate loci in idiopathic pulmonary fibrosis patients from four European populations. *Front. immunol.* 2016; 7: 274.
17. Van der Vis JJ, Snetselaar R, Kazemier KM, ten Klooster L, Grutters JC, van Moorsel CH. Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. *Respirology.* 2016; 21(4): 712–7.
18. Aquino-Gálvez A, González-Ávila G, Pérez-Rodríguez M, Partida-Rodríguez O, Nieves-Ramírez M, Piña-Ramírez I, et al. Analysis of heat shock protein 70 gene polymorphisms Mexican patients with idiopathic pulmonary fibrosis. *BMC Pulm. Med.* 2015; 15(1): 1-8.

19. Peljto AL, Selman M, Kim DS, Murphy E, Tucker L, Pardo A, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. *Chest*. 2015; 147(2): 460-4.
20. Zhang HP, Zou J, Xie P, Gao F, Mu HJ. Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis. *Kaohsiung J. Med. Sci.* 2015; 31: 613–20.
21. Zhang HT, Fang SC, Wang CY, Wang W, Wu J, Wang C, et al. MMP-9 1562C> T gene polymorphism and efficacy of glucocorticoid therapy in idiopathic pulmonary fibrosis patients. *Genet. Test. Mol. Biomark.* 2015; 19(11): 591-7.
22. Horimasu Y, Ohshimo S, Bonella F, Tanaka S, Ishikawa N, Hattori N, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. *Respirology*. 2015; 20(3): 439–44.
23. Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, et al. Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2016; 193(10): 1151–60.
24. Jiang H, Hu Y, Shang L, Li Y, Yang L, Chen Y. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. *Int. J. Clin. Exp. Pathol.* 2015; 8(11): 14953.
25. Wang C, Zhuang Y, Guo W, Cao L, Zhang H, Xu L, et al. Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. *PloS One*. 2014; 9(8): e104919.
26. Uh ST, Jang AS, Park SW, Park JS, Min CG, Kim YH, et al. ADAM33 gene polymorphisms are associated with the risk of idiopathic pulmonary fibrosis. *Lung*. 2014; 192(4): 525-32.
27. Sangiuolo F, Puxeddu E, Pezzuto G, Cavalli F, Longo G, Comandini A, et al. HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2015; 45(2): 483-90.

28. Coghlan MA, Shifren A, Huang HJ, Russell TD, Mitra RD, Zhang Q, et al. Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations. *BMJ Open Respir. Res.* 2014; 1(1).
29. Ohshimo S, Horimasu Y, Bonella F, Iwamoto H, Ishikawa N, Fujitaka K, et al. Angiotensin-converting enzyme 2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2014; 44.
30. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat. Genet.* 2013; 45(6): 613–20.
31. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. *Lancet Respir. Med.* 2013; 1(4): 309–17.
32. Uh ST, Kim TH, Shim EY, Jang AS, Park SW, Park JS, et al. Angiotensin-converting enzyme (ACE) gene polymorphisms are associated with idiopathic pulmonary fibrosis. *Lung.* 2013; 191(4): 345-51.
33. Wei R, Li C, Zhang M, Jones-Hall YL, Myers JL, Noth I, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. *Transl Res.* 2014; 163(5): 494–502.
34. Stock CJ, Sato H, Fonseca C, Banya WAS, Molyneaux PL, Adamali H, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. *Thorax.* 2013; 68(5): 436–41.
35. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, et al. The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population. *PLoS One.* 2013; 8(8).
36. Son JY, Kim SY, Cho SH, Shim HS, Jung JY, Kim EY, et al. TGF- $\beta$ 1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity. *Lung.* 2013; 191(2): 199–205.

37. Martinelli M, Scapoli L, Carbonara P, Valentini I, Girardi A, Farinella F, et al. Idiopathic pulmonary fibrosis and polymorphisms of the folate pathway genes. *Clin. Biochem.* 2013; 46(1-2): 85-8.
38. Korthagen NM, van Moorsel CHM, Barlo NP, Kazemier KM, Ruven HJT, Grutters JC. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. *PLoS One.* 2012; 7(1).
39. Zhang J, Xu DJ, Xu KF, Wu B, Zheng MF, Chen JY, et al. HLA-A and HLA-B gene polymorphism and idiopathic pulmonary fibrosis in a Han Chinese population. *Respir. Med.* 2012; 106(10): 1456-62.
40. Zhang Y, Noth I, Garcia JGN, Kaminski N. A Variant in the Promoter of MUC5B and Idiopathic Pulmonary Fibrosis. *N. Engl. J. Med.* 2011; 364(16): 1576-7.
41. Ahn MH, Park BL, Lee SH, Park SW, Park JS, Kim DJ, et al. A promoter SNP rs4073T> A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. *Respir. Res.* 2011; 12(1): 1-7.
42. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. *N Engl J Med.* 2011; 364(16): 1503-12.
43. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, et al. The HLA class II Allele DRB1\* 1501 is over-represented in patients with idiopathic pulmonary fibrosis. *PloS One.* 2011; 6(2): e14715.
44. Barlo NP, van Moorsel CHM, Korthagen NM, Heron M, Rijkers GT, Ruven HJT, et al. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1 $\beta$  in idiopathic pulmonary fibrosis. *Clin. Exp. Immunol.* 2011; 166: 346-51.
45. Li XX, Li N, Ban CJ, Zhu M, Xiao B, Dai HP. Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor- $\beta$ 1 and plasminogen activator inhibitor 1. *Chin. Med. J.* 2011; 124(13): 1923-7.
46. Yuan YD, Zhao MX, Yu J. Association between genetic polymorphism of erythrocyte CR1 and the susceptibility of idiopathic pulmonary fibrosis. *Chinese Journal of Tuberculosis and Respiratory Diseases.* 2011; 34: 841-5.

47. Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, et al. Copy number variation of FCGR3B is associated with susceptibility to idiopathic pulmonary fibrosis. *Respiration*. 2011; 81(2): 142–9.
48. Aquino-Galvez A, Pérez-Rodríguez M, Camarena Á, Falfan-Valencia R, Ruiz V, Montaña M, et al. MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility. *Hum. Genet.* 2009; 125(5): 639-48.
49. Liu L, Dai HP, Xiao B, Zhang S, Ban CJ, Xin P. Association of ENA-78, IP-10 and VEGF gene polymorphism with idiopathic pulmonary fibrosis. *Zhonghua yi xue za zhi*. 2009; 89(38): 2690-4.
50. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. *J. Med. Genet.* 2008; 45(10): 654–6.
51. Checa M, Ruiz V, Montaña M, Velázquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. *Hum. Genet.* 2008; 124(5): 465-72.
52. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. *Tissue Antigens*. 2006; 67(3): 229-32.
53. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. *J. Intern. Med.* 2004; 34(3): 126-9.
54. Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M, et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 2003; 168(3): 330-4.
55. Selman M, Lin HM, Montaña M, Jenkins AL, Estrada A, Lin Z, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. *Hum. Genet.* 2003; 113: 542–50.



56. Libby DM, Gibofsky A, Fotino M, Waters SJ, Smith JP. Immunogenetic and clinical findings in idiopathic pulmonary fibrosis: association with the B-cell alloantigen HLA-DR2. *Am. Rev. Respir. Dis.* 1983; 127(5): 618-22.
57. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 2001; 29(1): 308-11.
58. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. *Am J Respir Crit Care Med.* 2000; 161: 646–664.
59. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2002; 165: 277–304.
60. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Eur. Respir. J.* 2002; 19(5): 794-796
61. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011; 183: 788–824
62. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013; 188: 733–48.
63. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med.* 2018; 198(5): e44-68.
64. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax.* 2008; 63: v1–v58.